Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety

Sharvesh Raj Seeruttun; Sharvesh Raj Seeruttun

doi:10.3934/genet.2019.3.64

AIMS Genetics

2019, Volume 6, Issue 3: 64-66. doi: 10.3934/genet.2019.3.64

Previous Article Next Article

Editorial

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety

Sharvesh Raj Seeruttun ^,

Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, Guangdong, P. R. China

Received: 17 September 2019 Accepted: 18 September 2019 Published: 19 September 2019

Citation: Sharvesh Raj Seeruttun. Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety[J]. AIMS Genetics, 2019, 6(3): 64-66. doi: 10.3934/genet.2019.3.64

Related Papers:

References

[1]	Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264. doi: 10.1038/nrc3239
[2]	Byun DJ, Wolchok JD, Rosenberg LM, et al. (2017) Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13: 195-207. doi: 10.1038/nrendo.2016.205
[3]	Yan L, Zhang W (2018) Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun 38: 6. doi: 10.1186/s40880-018-0274-3
[4]	Brahmer JR, Tykodi SS, Chow LQ, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465. doi: 10.1056/NEJMoa1200694
[5]	Weber JS, Yang JC, Atkins MB, et al. (2015) Toxicities of Immunotherapy for the Practitioner. J Clin Oncol 33: 2092-2099. doi: 10.1200/JCO.2014.60.0379
[6]	Blank CU, Rozeman EA, Fanchi LF, et al. (2018) Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 24: 1655-1661. doi: 10.1038/s41591-018-0198-0
[7]	Chinese Journal of Cancer (2017) The 150 most important questions in cancer research and clinical oncology series: Questions 50-56. Chin J Cancer 36: 69. doi: 10.1186/s40880-017-0236-1
[8]	Rossi JF, Ceballos P, Lu ZY (2019) Immune precision medicine for cancer: A novel insight based on the efficiency of immune effector cells. Cancer Commun 39: 34. doi: 10.1186/s40880-019-0379-3
[9]	Devecchi A, De Cecco L, Dugo M, et al. (2018) The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer Commun 38: 70. doi: 10.1186/s40880-018-0339-3
[10]	Zhang Y, Du X, Liu M, et al. (2019) Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res 29: 609-627. doi: 10.1038/s41422-019-0184-1
[11]	Hou TZ, Verma N, Wanders J, et al. (2017) Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations. Blood 129: 1458-1468. doi: 10.1182/blood-2016-10-745174
[12]	Du X, Tang F, Liu M, et al. (2018) A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 28: 416-432. doi: 10.1038/s41422-018-0011-0

Reader Comments

Your name:*

Email:*
© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)